Collegium Pharmaceutical, Inc. Common Stock Stock Prediction
AI-powered sentiment analysis and prediction trends for COLL, updated each market day.
COLL AI Sentiment
AI sees no strong directional signal for Collegium Pharmaceutical, Inc. Common Stock stock over the next 10 market days.
Prediction date: April 30, 2026
Subscribers see precise scores, buy/sell targets, and full analytics.
About Collegium Pharmaceutical, Inc. Common Stock
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
Sector
Exchange
Market Cap
$1,046,096,959
Cap Tier
Employees
423
Headquarters
STOUGHTON, MA
Listed Since
May 7, 2015
Website
COLL Sentiment Trend — Last 30 Predictions
Sentiment zones: Bullish · Neutral · Bearish
COLL Volatility
Collegium Pharmaceutical, Inc. Common Stock has shown moderate price volatility over the last 5 trading days. Moderate volatility indicates normal market activity with typical price fluctuations.
